VolitionRx was one of two companies recently highlighted in an article published in Wall St. Cheat Sheet that emphasized the long-term impact of positive news and/or achievements in the biotechnology industry.
“One way to offset the current market uncertainty is to look for news driven stocks that appear to be paving the way for future growth. This is especially true in the biotechnology sector where one positive news announcement can help pave the way for years of innovation. Two companies that have released recent positive announcements include Medivation (NASDAQ:MDVN) and VolitionRx (VNRX.OB). Investors should keep their eyes on both of these promising companies.”
To read the full article visit http://wallstcheatsheet.com/stocks/2-biotechnology-stocks-with-a-bright-future.html/
Contributor Tom Meyer starts with a run-down of Medivation, a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases, such as cancer, for which there are limited treatment options. The company’s flagship product, XTANDI, is FDA-approved for the treatment of patients with metastatic castration-related prostate cancer who have previously been treated with chemotherapy.
As an introduction to life sciences company VolitionRx, Meyer describes the company’s goal to make non-invasive, simple-to-use cancer blood tests similar to the tests that are currently available for diabetics. VolitionRx’s R&D is currently centered in Belgium as the company is initially focused on marketing its products in Europe due to an easier path to regulatory approval there. The company’s primary focus at this time is on the colorectal cancer market, though its technology has the potential to be expanded into other cancers.
Meyer breaks-down into layman’s terms the science behind VolitionRx’s cancer blood tests, as well as the company’s ongoing clinical activities before concluding that:
“The colorectal cancer market is in need of much better diagnostics. The current available options include colonoscopies (invasive and expensive) and FIT/FOBT faecal-based tests (unpleasant and don’t screen for pre-cancerous polyps). If VolitionRx can successfully get some of its products to market, the company should see a dramatic climb in its share price. Also, investors should begin to see a run-up in the company’s share price as VolitionRx gets closer to revenue production.”
For more information, visit www.volitionrx.com
Let us hear your thoughts below:
